Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 17/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698864 | 0.87 | P2RX7 (0.55) | P2RX7MAPTTHRBMEN1USP2 | |
| SCHEMBL4750584 | 0.85 | P2RX7 (0.59) | P2RX7 | |
| SCHEMBL4696025 | 0.85 | P2RX7 (0.59) | P2RX7 | |
| SCHEMBL4699632 | 0.84 | P2RX7 (0.53) | P2RX7MAPTTHRB | |
| SCHEMBL5446699 | 0.80 | MEN1 (0.53) | MAPTTHRBMEN1USP2CYP3A4 | |
| SCHEMBL4753429 | 0.74 | P2RX7 (0.63) | P2RX7 | |
| SCHEMBL3590096 | 0.74 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL4755588 | 0.73 | P2RX7 (0.57) | P2RX7 | |
| SCHEMBL3292577 | 0.72 | P2RX7 (0.74) | P2RX7 | |
| SCHEMBL5448293 | 0.70 | P2RX7 (0.54) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963275-A2 | P2X7 RECEPTOR ANTAGONISTS AND USES THEREOF | Abbott Laboratories (US) | 2008-09-03 | — | — | EP | claimed |
| US-20070259920-A1 | P2X7, receptor antagonists and uses thereof | ABBOTT LABORATORIES | 2007-11-08 | — | — | US | claimed |
| WO-2007056091-A2 | 2-PHENYL-2H-PYRAZ0LE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-05-18 | — | — | WO | claimed |
| EP-1963273-A2 | SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20070259920-A1 | P2X7, receptor antagonists and uses thereof | ABBOTT LABORATORIES | 2007-11-08 | — | — | US | disclosed |
| WO-2007075783-A2 | SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITOR | WYETH (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259920-A1 | P2X7, receptor antagonists and uses thereof | P2RX7, P2RX1, P2RX3 | P2RX7 1/4885MAPT 3930/4885THRB 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.